Document:

EX-4.3

 Exhibit 4.3 

EXECUTION VERSION 
  

 
 PAYING AND CALCULATION AGENCY
AGREEMENT 
 Dated July 8, 2015 

among 
 DH Europe Finance S.A.

 as Issuer 
 Danaher
Corporation 
 as Guarantor 
 and

 The Bank of New York Mellon, London Branch 

as Paying and Calculation Agent 

and 
 The Bank of New York Mellon
Trust Company N.A. 
 as Trustee 
  

 

 THIS AGREEMENT is made as of July 8, 2015, among DH Europe Finance S.A. (the
“Issuer”), whose principal office is at 1B Heienhaff, L-1736 Senningerberg, Grand Duchy of Luxembourg, Danaher Corporation (the “Guarantor”), whose principal office is at 2200 Pennsylvania Avenue, N.W., Suite 800W,
Washington, D.C. 20037-1701, The Bank of New York Mellon, London Branch, as Paying and Calculation Agent (the “Paying and Calculation Agent”), whose principal office is at One Canada Square, London E 1 4 5AL, United Kingdom and The
Bank of New York Mellon Trust Company, N.A., as Trustee (the “Trustee”), whose principal office is at 2 North LaSalle, Suite 1020, Chicago, Illinois 60602. 

WHEREAS, the Issuer proposes to issue €600,000,000 aggregate principal amount of 1.000% senior notes due 2019 (the “2019
Notes”), €800,000,000 aggregate principal amount of 1.700% senior notes due 2022 (the “2022 Notes”), €800,000,000 aggregate principal amount of 2.500% senior notes due 2025 (the “2025 Notes” and,
together with the 2019 Notes and the 2022 Notes, the “Fixed Rate Notes”) and €500,000,000 aggregate principal amount of floating rate senior notes due 2017 (the “Floating Rate Notes” and, together with the
Fixed Rate Notes, the “Notes”), in each case, on the date hereof, pursuant to that certain indenture dated as of July 8, 2015 (the “Base Indenture”) among the Issuer, the Guarantor and the Trustee, and that
certain first supplemental indenture among the Issuer, the Guarantor, and the Trustee (the “Supplemental Indenture” and together with the Base Indenture, the “Indenture”), the forms of which Indenture are attached
hereto as Annex A; and 
 WHEREAS, solely with respect to the Notes, the Issuer wishes to appoint the Paying and Calculation Agent, as set
forth above, upon the terms and subject to the conditions set forth herein; 
 NOW, THEREFORE, in consideration of the mutual promises
contained herein, the parties hereto agree as follows: 
  

	1.	DEFINITIONS 

 1.1 All capitalized terms used herein, but not defined, shall have the
meanings given to them in the Indenture. 
 1.2 In addition, the following terms shall have the following meanings: 

“Additional Amounts” shall have the meaning set forth in the Notes. 

“Business Day” means any day other than a Saturday or Sunday, (i) which is not a day on which banking institutions in The
City of New York or London are authorized or required by law, regulation or executive order to close and (ii) in the event that any payment by the Issuer of the principal of and interest on, the Notes is to be made in Euro, on which the
Trans-European Automated Real Time Gross Settlement Express Transfer system (the TARGET2 system), or any successor thereto, is open. 

“Code” means the US Internal Revenue Code of 1986, as amended. 

“FATCA Compliant Entity” means an entity not subject to FATCA Withholding Tax. 

“FATCA Withholding Tax” means any withholding or deduction pursuant to an agreement described in Section 1471(b) of the
Code or otherwise imposed pursuant to Sections 1471 through 1474 of the Code (or any regulations or agreements thereunder or official interpretations thereof) or any intergovernmental agreement between the United States and another jurisdiction
facilitating the implementation thereof (or any law implementing such an intergovernmental agreement). 
 References to the records of
Euroclear Bank S.A./N.V. (“Euroclear”) and Clearstream Banking, société anonyme (“Clearstream”) shall be to the records that each of Euroclear and Clearstream holds for its customers which reflect the
amount of such customers’ interests in the Notes. 

	2.	APPOINTMENT OF PAYING AND CALCULATION AGENT AND AS COMMON DEPOSITARY 

 The Issuer hereby
appoints the Paying and Calculation Agent at its office specified above as the Paying and Calculation Agent solely in respect of the Notes and as the common depositary for Euroclear and Clearstream for the Notes, in each case, upon the terms and
conditions herein contained, and the Paying and Calculation Agent accepts such appointments. In the event of any inconsistency between the Indenture and this Agreement, the terms of this Agreement (including the Annexes attached thereto) shall
prevail. 
  

	3.	PAYMENT 

 3.1 In order to provide for all payments due on the Notes as the same shall
become due, the Issuer shall cause to be paid to the Paying and Calculation Agent, no later than 10:00 a.m. London time one Business Day prior to the due date for the payment of each Note, at such bank as the Paying and Calculation Agent shall
previously have notified to the Issuer, an amount in immediately available funds in the currency of payment sufficient to meet all payments due on such Notes. 

3.2 The Issuer hereby authorizes and directs the Paying and Calculation Agent, solely from the amounts paid to it pursuant to this
Section 3, to make or cause to be made all payments on the Notes in accordance with the terms thereof. Such payments shall be made to the Holder or Holders of Notes in accordance with the terms of the Notes, the provisions contained in this
Agreement and the procedures of Euroclear and Clearstream. All interest payments and Additional Amounts, if any, in respect of the Notes will be made by the Paying and Calculation Agent on the relevant Interest Payment Date (as set forth in the
Note) to the Holders in whose names the Notes are registered at the close of business (in New York) on the record date specified in the Notes next preceding the relevant Interest Payment Date or such other date as is provided in the Notes. So long
as the Notes are represented by a single global certificate and registered in the name of a common depository for Euroclear and Clearstream or its nominee, all interest payments and Additional Amounts, if any, on the Notes shall be made by the
Paying and Calculation Agent by wire transfer of immediately available funds in Euro to Euroclear and Clearstream. 
 3.3 The Paying and
Calculation Agent will pay the principal amount of each Note on the applicable maturity date or upon any redemption date with respect thereto, together with accrued and unpaid interest and Additional Amounts, if any, due at maturity or such
redemption date, if any, upon presentation and surrender of such Note on or after the maturity date or redemption date thereof to the Paying and Calculation Agent, or as specified in the Notes. 

3.4 If for any reason the amounts received by the Paying and Calculation Agent are insufficient to satisfy all claims in respect of all
payments then due on the Notes, the Paying and Calculation Agent shall forthwith notify the Issuer, and the Paying and Calculation Agent shall not be obliged to pay any such claims until the Paying and Calculation Agent has received from the Issuer
the full amount of the monies then due and payable in respect of such Notes. 
 3.5 The Paying and Calculation Agent hereby agrees that:

  

	 	(a)	it will hold all sums held by it as Paying and Calculation Agent for the payment of the principal of or interest and Additional Amounts, if any, on the Notes in trust uninvested for the benefit of the Holders of the
Notes entitled thereto, or for the benefit of the Trustee, as the case may be, until such sums shall be paid out to such Holders or otherwise as provided in Section 3.6 below and in the Indenture; 

 

	 	(b)	it will promptly give the Trustee notice of: (x) an Issuer deposit for the payment of principal of or interest, and Additional Amounts, if any, on the Notes, (y) any failure by the Issuer in the making of any
deposit for the payment of principal of or interest, and Additional Amounts, if any, on the Notes that shall have become due and payable, and (z) any default by the Issuer in making any payment of the principal of or interest, and Additional
Amounts, if any, on the Notes where the same shall be due and payable as provided in the Notes; and 

  

	 	(c)	At any time after an Event of Default by the Issuer in the making of any payment of principal of, or interest on, or any Additional Amounts with respect to the Notes shall have occurred (after giving effect to any
applicable grace period under the Notes and the Indenture), the Paying and Calculation Agent shall, if so required by notice in writing given by the Trustee to the Paying and Calculation Agent: (y) thereafter, until otherwise instructed by the
Trustee, act as agent of the Trustee under the terms of the Indenture; and/or (z) deliver all Notes and all sums, documents and records held by the Paying and Calculation Agent in respect of the Notes to the Trustee or as the Trustee shall
direct in such notice; provided that such notice shall be deemed not to apply to any document or record which the Paying and Calculation Agent is obliged not to release by any applicable law or regulation. 

 3.6 Notwithstanding the foregoing, 

 

	 	(a)	if any Note is presented or surrendered for payment to the Paying and Calculation Agent and the Paying and Calculation Agent has delivered a replacement therefor or has been notified that the same has been replaced, the
Paying and Calculation Agent shall as soon as is reasonably practicable notify the Issuer in writing of such presentation or surrender and shall not make payment against the same until it is so instructed by the Issuer and has received the amount to
be so paid; and 

  

	 	(b)	the Paying and Calculation Agent shall cancel each Note against surrender of which it has made full payment and shall deliver each Note so cancelled by it to the Trustee upon its request therefor. 

3.7 In no event, shall the Paying and Calculation Agent be obliged to make any payments hereunder if it has not received the full amount of
any such payment. 
  

	4.	CALCULATION OF INTEREST 

 4.1 The Paying and Calculation Agent shall calculate the amount
of interest payable on the Notes in the manner and at the times set forth in Annex A and in the Prospectus Supplement in respect of the Notes attached hereto as Annex B. 

4.2 As soon as practicable after each Interest Determination Date (as defined in the Notes), the Paying and Calculation Agent will cause to be
forwarded to the Issuer and the Trustee information regarding the interest rates, the interest periods, the amount of interest for each interest period and the relevant Interest Payment Date. The Paying and Calculation Agent will, upon the written
request of any Holder of any Note, provide the interest rate then in effect and, if determined, the interest rate which will become effective for the next interest period with respect to such Note. 

4.3 In no event shall the interest rate be less than the minimum rate, if any, or more than the maximum rate, if any, designated in the
applicable pricing supplement, or more than the maximum rate permitted by New York law, as the same may be modified by United States law of general application. 
  

	5.	INDEMNITY 

 5.1 Each of the Issuer and the Guarantor, jointly and severally, shall
indemnify and keep indemnified the Paying and Calculation Agent against any losses, liabilities, costs, claims, actions or demands incurred by it as a result of or in connection with its appointment or the exercise of its powers and duties under
this Agreement or in respect of the Issuer’s issue of Notes, except to the extent resulting from the Paying and Calculation Agent’s bad faith, gross negligence or willful misconduct. Promptly after the receipt by the Paying and Calculation
Agent of notice of any demand or claim or the commencement of any action, suit, proceeding or investigation, the Paying and Calculation Agent shall provide such notice to the Issuer; provided that the Paying and Calculation Agent’s
failure to provide such notice shall, to the extent that the Issuer or the Guarantor, as applicable, is prejudiced as a result of such failure, relieve the Issuer or the Guarantor of its obligation to indemnify and keep indemnified the Paying and
Calculation Agent pursuant to this Section 5.1. 

 5.3 The Issuer, in its sole discretion, may elect to assume the defense of any such claim, in
which case the Paying and Calculation Agent shall cooperate in the defense of such claim. The Paying and Calculation Agent may have separate counsel in any such defense, but the fees and expenses of any such counsel shall be at the expense of the
Paying and Calculation Agent, unless: (i) the employment of such counsel has been specifically authorized in writing by the Issuer or (ii) the named parties to any such action (including any impleaded parties) include both the Paying and
Calculation Agent and the Issuer or any affiliate of the Issuer, and such Paying and Calculation Agent shall have reasonably concluded that, in the written opinion of counsel, an actual conflict of interest exists between the Paying and Calculation
Agent and the Issuer or such affiliate of the Issuer. The Issuer shall not be required to pay for or agree to any settlement without its written consent. 

5.4 In connection with its execution of and acting under this Agreement, the Trustee is entitled to all rights, privileges, protections,
benefits, immunities and indemnities (i) provided to it under the Indenture and (ii) provided to the Paying and Calculation Agent hereunder. 

5.5 The indemnities contained in Sections 5.1 and 5.2 shall survive the termination or expiry of this Agreement and the resignation or removal
of the Paying and Calculation Agent. 
  

	6.	GENERAL 

 6.1 In acting under this Agreement, the Paying and Calculation Agent shall not
(a) be under any fiduciary duty towards any person, (b) be responsible for or liable in respect of the authorization, validity or legality of any Note amount paid by it hereunder (except to the extent that any such liability is determined
by a court of competent jurisdiction to have been resulted from the Paying and Calculation Agent’s bad faith, gross negligence or wilful misconduct), (c) be under any obligation towards any person other than the Trustee and Issuer or
(d) assume any relationship of agency or trust for or with any Holder. 
 6.2 Except as otherwise permitted hereunder or as ordered by
a court of competent jurisdiction or required by law or otherwise instructed by the Issuer, the Paying and Calculation Agent shall be entitled to treat the registered Holder of any Note as the absolute owner of such Note for all purposes and make
payments thereon accordingly. 
 6.3 The Paying and Calculation Agent shall not exercise any lien, right of set-off or similar claim against
any Holder of a Note in respect of moneys payable by it under this Agreement. 
 6.4 The Paying and Calculation Agent may consult on any
matter concerning its duties hereunder any legal adviser selected by it, and the Paying and Calculation Agent shall not be liable in respect of anything done, or omitted to be done in reasonable, good faith reliance on that legal adviser’s
opinion. At any time, the Paying and Calculation Agent may apply to any duly authorized representative of the Issuer for a written instruction, and shall not be liable for action taken or omitted to be taken in good faith and in accordance with such
instruction. 
 6.5 The Paying and Calculation Agent shall be entitled to rely, and shall not be liable in respect of anything done or
suffered by it in reliance, on any notice, document, communication or information reasonably believed in good faith by it to be genuine and given by the proper parties. 

6.6 The Paying and Calculation Agent shall be obliged to perform only such duties as are specifically set forth herein and in the Notes, and
no implied duties or obligations shall be read into this Agreement or the Notes against the Paying and Calculation Agent. 
 6.7 Subject as
provided in subsection 6.3 above, the Paying and Calculation Agent shall not be liable to account to the Issuer for any interest or other amounts in respect of funds received by it hereunder from the Issuer. Money held by the Paying and Calculation
Agent need not be segregated except as required by law. 

 6.8 No provision of this Agreement or the Notes shall require the Paying and Calculation Agent to
risk or expend its own funds, or to take any action which in its reasonable judgment would result in any expense or liability accruing to it. 

6.9 In no event will the Paying and Calculation Agent be responsible or liable for any failure or delay in the performance of its obligations
hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, acts of war or terrorism, civil or military disturbances, nuclear or natural catastrophes or acts of God, and interruptions, severe loss or
malfunctions of utilities, communications or computer (software and hardware) services; it being understood that the Paying and Calculation Agent will use reasonable best efforts to resume performance as soon as practicable. 

6.10 The Paying and Calculation Agent shall have no duty to enquire as to the performance of the covenants of the Issuer, nor shall it be
charged with knowledge of any default or Event of Default under the Indenture. 
 6.11 Notwithstanding any provision of this Agreement to
the contrary, the Paying and Calculation Agent will not in any event be liable for special, punitive or consequential loss or damage of any kind whatsoever (including but not limited to lost profits), whether or not foreseeable, even if the Paying
and Calculation Agent has been advised of the likelihood of such loss or damage and regardless of the form of action. 
 6.12 Except to the
extent otherwise provided in this Agreement, the Paying and Calculation Agent shall incur no liability hereunder except to the extent such liability has been determined to arise from the Paying and Calculation Agent’s bad faith, gross
negligence or willful misconduct. 
 6.13 The Paying and Calculation Agent, its officers, directors, employees and shareholders may become
the owners of, or acquire any interest in, the Notes, with the same rights that it or they would have if it were not the Paying and Calculation Agent, and may engage or be interested in any financial or other transaction with the Issuer as freely as
if it were not the Paying and Calculation Agent. 
 6.14 The Paying and Calculation Agent shall retain the right not to act and shall not be
held liable for refusing to act unless it has received clear and reasonable documentation which complies with the terms of this Agreement. 

6.15 The Issuer will supply the Paying and Calculation Agent with the names and specimen signatures of its authorized persons. 

 

	7.	CHANGE OF PAYING AND CALCULATION AGENT 

 7.1 At any time, other than on a day during the
forty-five (45) day period preceding any payment date on the Notes, the Paying and Calculation Agent may resign by giving at least forty-five (45) days’ prior written notice to Issuer; and the Paying and Calculation Agent’s
agency shall be terminated and its duties shall cease upon expiration of such forty-five (45) days or such lesser period of time as shall be mutually agreeable to Paying and Calculation Agent and Issuer. At any time, following at least
forty-five (45) days’ prior written notice (or such lesser period of time as shall be mutually agreeable to the Paying and Calculation Agent and the Issuer) from the Issuer, the Paying and Calculation Agent may be removed from its agency.
Such removal shall become effective upon the expiration of the forty-five (45) day or agreed lesser time period, and upon payment to the Paying and Calculation Agent of all amounts due and payable to it in connection with its agency. In such
event, following payment of its fees and expenses due and payable, the Paying and Calculation Agent shall deliver to the Issuer, or to the Issuer’s designated representative, all Notes (if any) and cash (if any) belonging to the Issuer and, at
the Issuer’s expense, shall furnish to the Issuer, or to the Issuer’s designated representative, such information regarding the status of the Issuer’s outstanding Notes reasonably requested by the Issuer. 

7.2 Any corporation into which the Paying and Calculation Agent may be merged or consolidated or any corporation resulting from any merger or
consolidation to which the Paying and Calculation Agent is a party or any corporation to which the Paying and Calculation Agent shall sell or otherwise transfer all or substantially all of its corporate trust or agency assets shall on the date on
which such merger, consolidation or transfer becomes effective, become the successor to the Paying and Calculation Agent under this Agreement without the execution or filing of any paper or any further act on the part of the parties hereto. 

	8.	COMPENSATION AND FEES 

 8.1 The Issuer or the Guarantor, as applicable, will pay to the
Paying and Calculation Agent from time to time, compensation as shall be agreed to in writing between the Issuer and the Paying and Calculation Agent in connection with its duties hereunder, together with any applicable value added tax and stamp,
issue, or other documentary taxes and duties. In addition, the Issuer or the Guarantor, as applicable, shall reimburse the Paying and Calculation Agent, upon the Paying and Calculation Agent’s request, for all reasonable out of pocket expenses
and disbursements incurred by the Paying and Calculation Agent in accordance with the provisions of this Agreement (including the reasonable compensation, expenses and disbursements of any outside counsel for the Paying and Calculation Agent),
except any expense or disbursement attributable to its gross negligence, willful misconduct or bad faith. 
  

	9.	NOTICES 

 9.1 Each notice or communication under this Agreement shall be made in writing,
by fax or otherwise in accordance with this Section 9. Each communication or document to be delivered to any party under this Agreement shall be sent to that party at the fax number or address, and marked for the attention of the person (if
any), from time to time designated by that party to the Paying and Calculation Agent (or, in the case of the Paying and Calculation Agent, by it to each other party) for the purpose of this Agreement. The initial telephone number, fax number,
address and person so designated are: 
 in the case of the Issuer or the Guarantor, to it at: 

 

			
	 c/o Danaher Corporation
 2200
Pennsylvania Avenue, N.W., Suite 800W,
 Washington, D.C. 20037-1701.

	Attention:        		Vice President-Treasurer
	Fax:		(202) 828-0860

 in the case of the Paying and Calculation Agent, to it at: 

 

			
	The Bank of New York Mellon (London Branch)
	One Canada Square, London El4 5AL, United Kingdom
	Attention: Corporate Trust Administration
	Fax: +44 (0) 20 7964 2536
	Email: corpsovl@bnymellon.com

 in the case of the Trustee, to it at: 

 

			
	The Bank of New York Mellon Trust Company, N.A.
	2 North LaSalle, Suite 1020, Chicago, Illinois 60602.
	Attention:        		Corporate Finance
	Fax:		(312) 827-8542

 9.2 All notices under this Agreement shall be effective (if by fax) when good receipt is confirmed by the
recipient following enquiry by the sender and (if in writing) when delivered, except that a communication received outside normal business hours shall be deemed to be received on the next business day in the city in which the recipient is located.

 9.3 The Paying and Calculation Agent agrees to accept and act upon instructions or directions pursuant to this Agreement sent by
unsecured e-mail, PDF, facsimile transmission or other similar unsecured electronic methods, provided that the Paying and Calculation Agent shall have received an incumbency certificate listing persons authorized to give such instructions or
directions and containing specimen signatures of such 

 
authorized persons, which such incumbency certificate shall be amended and replaced whenever a person is to be added or deleted from the listing. Subject to Article V and Section 6.12 of
this Agreement, in no event shall the Paying and Calculation Agent be liable for any losses resulting from the Paying and Calculation Agent receiving from an authorized person via any non-secure method of transmission or communication, such as by
facsimile or email. The Paying and Calculation Agent is authorized to comply with and rely upon any such notice, instruction or other communications reasonably believed by it to have been sent or given by an authorized person. The Issuer shall use
all reasonable endeavours to ensure that instructions transmitted to the Paying and Calculation Agent pursuant to this Agreement are complete and correct. Any instructions properly delivered pursuant to the requirements of this agreement shall be
conclusively deemed to be valid instructions from the Issuer to the Paying and Calculation Agent for the purposes of this Agreement. 
  

	10.	GOVERNING LAW AND JURISDICTION; WAIVER OF JURY TRIAL 

 10.1 The interpretation, validity
and enforcement of this Agreement, and all legal actions brought under or in connection with the subject matter of this Agreement, shall be governed by the laws of the State of New York. 

10.2 Any court action brought under or in connection with the subject matter of this Agreement shall be brought only in any federal or New
York State court, in either case, sitting in the Borough of Manhattan, City of New York. Each of the Issuer and the Paying and Calculation Agent submits to the exclusive jurisdiction of these courts and agrees not to commence any legal action under
or in connection with the subject matter of this Agreement in any other court or forum. 
 10.3 Each of the Issuer, the Trustee and the
Paying and Calculation Agent waives any objection to the laying of the venue of any legal action brought under or in connection with the subject matter of this Agreement in the Federal or state courts sitting in the Borough of Manhattan, City of New
York, and agrees not to plead or claim in such courts that any such action has been brought in an inconvenient forum 
 10.4 EACH OF THE
ISSUER, THE GUARANTOR, THE HOLDERS OF THE NOTES, THE TRUSTEE AND THE PAYING AND CALCULATION AGENT HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF
OR RELATING TO THIS AGREEMENT OR THE TRANSACTION CONTEMPLATED HEREBY. 
  

	11.	WITHHOLDING 

 11.1 Notwithstanding any other provision of this Agreement, the Paying and
Calculation Agent or Trustee (as applicable, “BNYM”) shall be required to make a deduction or withholding (including the deduction of FATCA Withholding Tax) from any payment which it makes under this Agreement for or on account of
any present or future taxes, duties or charges if and to the extent so required by any applicable law and any current or future regulations or agreements thereunder or official interpretations thereof or any law implementing an intergovernmental
approach thereto or by virtue of the relevant holder failing to satisfy any certification or other requirements in respect of the Notes (the “Applicable Law”), in which event BNYM shall make such payment after such withholding or
deduction has been made and shall account to the relevant authorities for the amount so withheld or deducted, and BNYM shall have no obligation to gross up any payment hereunder or pay any Additional Amount as a result of such withholding tax. 

11.2 If the Paying and Calculation Agent or Trustee is a “foreign financial institution” as such term is defined under FATCA, then
such Paying and Calculation Agent or Trustee must be or become, prior to receiving any payment from the Issuer under this Agreement, a FATCA Compliant Entity. Notwithstanding any other paragraph herein, any additional, substitute or successor Paying
and Calculation Agent or Trustee appointed under this Agreement that is a foreign financial institution must be a FATCA Compliant Entity. 

11.3 If, for any reason, the Paying and Calculation Agent or Trustee is not, or ceases to be, a FATCA Compliant Entity and, as a result, the
Issuer considers in its sole discretion that it may be required to deduct or withhold FATCA Withholding Tax in respect of any payment due on any Notes, then the Issuer will be entitled to redirect or reorganise any such payment in any way that it
sees fit in order that the payment may be made without 

 
such FATCA Withholding Tax. In order to comply with Applicable Law, the Company agrees: (i) to provide to BNYM reasonably sufficient information about holders or other applicable parties
and/or transactions (including any modification to the terms of the Notes), to the extent such information is in the possession of the Company, so BNYM can determine whether it has tax related obligations under Applicable Law and (ii) that BNYM
shall be entitled to make any withholding or deduction from payments under the transaction documents to the extent necessary to comply with Applicable Law. 

[signature pages follow] 

 IN WITNESS WHEREOF the parties hereto have caused this Agreement to be duly executed the day and
year first above written. 
  

					
	 DH EUROPE FINANCE S.A.
 as
Issuer

		
	By:		 /s/ Frank T. McFaden

			Name:		Frank T. McFaden
			Title:		Director
	
	DANAHER CORPORATION
	as Guarantor
		
	By:		 /s/ Daniel L. Comas

			Name:		Daniel L. Comas
			Title:		Executive Vice President and Chief Financial Officer
	
	THE BANK OF NEW YORK MELLON
	as Paying Agent and Calculation Agent
		
	By:		 /s/ Latoya S. Elvin

			Name:		Latoya S. Elvin
			Title:		Vice President
	
	THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A.
	as Trustee
		
	By:		 /s/ Lawrence M. Kusch

			Name:		Lawrence M. Kusch
			Title:		Vice President

  

 ANNEX A 

FORMS OF NOTES AND INDENTURE 

 ANNEX B 

PROSPECTUS SUPPLEMENTEX-4.2

 Exhibit 4.2 

Execution Version 

GLOBAL BLOOD THERAPEUTICS, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (“Agreement”) is made as of December 22, 2014, by and among
Global Blood Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”. 

RECITALS: 

WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of the Company’s Series A Preferred
Stock and possess registration rights, information rights, rights of first offer, and other rights pursuant to an Investors’ Rights Agreement dated as of May 31, 2012, by and among the Company and such Investors (as amended, the
“Prior Agreement”); 
 WHEREAS, the Existing Investors are holders of at least seventy-five percent (75%) of
the Registrable Securities (as defined in the Prior Agreement), and desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior
Agreement; 
 WHEREAS, the Company and certain Investors are parties to the Series B Preferred Stock Purchase Agreement of even date
herewith (the “Purchase Agreement”) under which certain of the Company’s and such Investors’ obligations are conditioned upon the execution and delivery of this Agreement by such Investors, Existing Investors holding at
least such amount of the Registrable Securities (as defined in the Prior Agreement) as would be required to amend and restate the Prior Agreement and the Company; and 

WHEREAS, in order to induce the Company to enter into the Purchase Agreement and to induce the Investors party to the Purchase
Agreement to invest funds in the Company pursuant to the Purchase Agreement, the Investors and the Company hereby agree that this Agreement shall govern the rights of the Investors to cause the Company to register shares of Common Stock issuable to
the Investors, to receive certain information from the Company, and to participate in future equity offerings by the Company, and shall govern certain other matters as set forth in this Agreement; 

NOW, THEREFORE, the Existing Investors hereby agree that the Prior Agreement shall be amended, restated and superseded by this
Agreement, and parties hereby further agree as follows: 
 1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, with respect to any specified Person, any other Person who or which, directly or indirectly,
controls, is controlled by, or is under common control with such specified Person, including without limitation any general partner, officer, director, or manager of such Person and any venture capital or other fund now or hereafter existing that is
controlled by one or more general partners or managing members of, or shares the same management company or investment advisor with, such Person. 

 1.2 “Board of Directors” means the Company’s Board of
Directors. 
 1.3 “Common Stock” means shares of the Company’s common stock, par
value $0.001 per share. 
 1.4 “Company’s Certificate of Incorporation” means the Second Amended and
Restated Certificate of Incorporation of the Company, as amended and/or restated from time to time. 
 1.5
“Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or
liability (or any action in respect thereof) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or
final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or
(iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the
Exchange Act, or any state securities law. 
 1.6 “Derivative Securities” means any securities or rights
convertible into, or exercisable or exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants. 

1.7 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder. 
 1.8 “Excluded Registration” means (i) a registration relating to the sale of securities
to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; or (iii) a registration on any form that does not include substantially
the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities. 

1.9 “Form S-1” means such form under the Securities Act as in effect on
the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 
 1.10
“Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation
of substantial information by reference to other documents filed by the Company with the SEC. 
 1.11 “GAAP”
means generally accepted accounting principles in the United States. 

  
 2 

 1.12 “Holder” means any holder of Registrable Securities who is a party to this
Agreement. 
 1.13 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse,
sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, of a natural person referred to herein. 

1.14 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.

 1.15 “IPO” means the Company’s first underwritten public offering of its Common Stock under the Securities Act.

 1.16 “Key Employee” means any executive-level employee (including division director and vice president-level positions).

 1.17 “Major Investor” means any Investor that, individually or together with such Investor’s Affiliates, holds at
least 1,000,000 shares of Registrable Securities (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization effected after the date hereof). 

1.18 “New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as
rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities, other than Exempted Securities (as such term
is defined in the Company’s Certificate of Incorporation). 
 1.19 “Person” means any individual, corporation,
partnership, trust, limited liability company, association or other entity. 
 1.20 “QPO” shall have the meaning set forth
in the Company’s Certificate of Incorporation. 
 1.21 “Registrable Securities” means (i) the Common Stock
issuable or issued upon conversion of the Series A Preferred Stock and the Series B Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities
of the Company, held by the Investors or acquired by a holder of Series A Preferred Stock or Series B Preferred Stock after the date hereof; (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or
other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any
Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Section 6.1, and excluding for purposes of Section 2 any shares for which registration
rights have terminated pursuant to Section 2.13 of this Agreement; and (iv) any other Common Stock subsequently acquired by an Investor, without duplication of any securities referred to in clauses (i) through
(iii) hereof. 

  
 3 

 1.22 “Registrable Securities then outstanding” means the number of shares at a
point in time determined by adding the number of shares of outstanding Common Stock that are Registrable Securities at such time and the number of shares of Common Stock issuable (directly or indirectly) at such time pursuant to then exercisable
and/or convertible securities that are Registrable Securities. 
 1.23 “Restricted Securities” means the securities of the
Company required to bear the legend set forth in Section 2.12(b) hereof. 
 1.24 “SEC” means the Securities and
Exchange Commission. 
 1.25 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act, or any
successor provisions. 
 1.26 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act, or any
successor provisions. 
 1.27 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder. 
 1.28 “Selling Expenses” means all underwriting discounts, selling commissions, and stock
transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Section
2.6. 
 1.29 “Selling Holder Counsel” shall have the meaning assigned to it in Section 2.6. 

1.30 “Series A Directors” means the directors of the Company that have been solely designated by the holders of record of the
Series A Preferred Stock pursuant to the Company’s Certificate of Incorporation, the Stockholders Agreement or otherwise. 
 1.31
“Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value $0.001 per share. 
 1.32
“Series B Preferred Stock” means shares of the Company’s Series B Preferred Stock, par value $0.001 per share. 
 1.33
“Stockholders Agreement” means the Amended and Restated Stockholders Agreement dated as of the date hereof and as may be amended from time to time, by and among the Company, the Investors, and Key Holders (as defined therein). 

  
 4 

 2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration 

(a) Form S-1 Demand. Beginning upon the earlier of (i) five (5) years after the date of this Agreement or (ii) six
(6) months after the effective date of the registration statement for the IPO, if the Company receives a request from Holders of at least twenty-five percent (25%) of the Registrable Securities then outstanding that the Company file a Form
S-1 registration statement with respect to at least twenty-five percent (25%) of the Registrable Securities then outstanding, having the anticipated aggregate offering amount of at least $3 million, then the Company shall (i) within ten
(10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within sixty (60) days
after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable
Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days after the date the Demand Notice is given, and in each case, subject to the
limitations of Section 2.1(c) and Section 2.3. 
 (b) Form S-3 Demand. If at any time when it is eligible to
use a Form S-3 registration statement, the Company receives a request from Holders of at least twenty-five percent (25%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to
outstanding Registrable Securities of such Holders having an anticipated aggregate offering amount, net of Selling Expenses, of at least $1 million, then the Company shall (i) within ten (10) days after the date such request is given, give
a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders, file a Form S-3 registration
statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days after the date
the Demand Notice is given, and in each case, subject to the limitations of Section 2.1(c) and Section 2.3. 
 (c)
Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Section 2.1 a certificate signed by the Company’s chief executive officer or other most senior executive
officer then in office stating that in the good faith judgment of the Board of Directors it would be materially detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as
long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the
Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or
Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than one hundred
twenty (120) days after the request of the Initiating Holders is given; provided, however, that the 

  
 5 

 
Company may not invoke this right more than once in any twelve (12) month period, nor shall the Company invoke this right more than twice in all periods; and provided further that the
Company shall not register any securities for its own account or that of any other stockholder during either one hundred twenty (120) day period other than an Excluded Registration. 

(d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(a)
(i) if it delivers notice to the Holders within thirty (30) days after any registration request of its intent to file a registration statement for a public offering within ninety (90) days; (ii) during the period that is one
hundred eighty (180) days after commencing a Company-initiated registration; (iii) after the Company has effected two (2) registrations pursuant to Section 2.1(a); or (iv) if the Initiating Holders propose to dispose
of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration
pursuant to Section 2.1(b) if the Company has effected two (2) registrations pursuant to Section 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be
counted as “effected” for purposes of this Section 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such
registration (other than as a result of a material adverse change to the Company), elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which case
such withdrawn registration statement shall be counted as “effected” for purposes of this Section 2.1(d). 
 2.2
Company Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the
public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days
after such notice is given by the Company, the Company shall, subject to the provisions of Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The
Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such
registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Section 2.6. 

2.3 Underwriting Requirements. 

(a) If, pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request
by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the
Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such
Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the 

  
 6 

 
extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in Section 2.4(e)) enter into an
underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Section 2.3, if the managing underwriter(s) advise the Initiating Holders in writing that
marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be
included in the underwriting shall be allocated among such Holders, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each, or in such other proportion as shall mutually be
agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the
underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. 

(b) In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to
Section 2.2, the Company shall not be required to include any of the Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then
only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by Holders to be included in
such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the
offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than
all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable)
to the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company
or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless all other
securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be reduced below thirty percent (30%) of the total number of
securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities are included in
such offering. For purposes of the provision in this Section 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired
members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed

  
 7 

 
to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by
all Persons included in such “selling Holder,” as defined in this sentence. 
 (c) For purposes of Section 2.1, a
registration shall not be counted as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Section 2.3(a) and (b), less than the total number of Registrable Securities that Holders have requested to
be included in such registration statement are actually included. 
 2.4 Obligations of the Company. Whenever required under this
Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred
twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time
equal to the period the Holder refrains, at the request of an underwriter of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are
intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended for up to one hundred eighty (180) days, if necessary, to keep the
registration statement effective until all such Registrable Securities are sold; 
 (b) prepare and file with the SEC such amendments and
supplements to such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such
registration statement; 
 (c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus,
as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general consent to service of process in any
such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 

  
 8 

 (f) use its commercially reasonable efforts to cause all such Registrable Securities covered by
such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number
for all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h) promptly make available
for inspection by the selling Holders, any underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders,
all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such
seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 
 (j) after such
registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. 

2.5 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this
Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of
such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 
 2.6 Expenses of
Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and
accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements of one counsel for the selling Holders (“Selling Holder Counsel”) selected by the Holders of at least sixty-six and two
thirds percent (66 2/3%) of the Registrable Securities, shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to
Section 2.1 if the registration request is subsequently withdrawn at the request of the Holders of at least sixty-six and two thirds percent (66 2/3%) of the Registrable Securities to be registered (in which case all selling Holders
shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one
registration pursuant to Section 2.1(a) or Section 2.1(b), 

  
 9 

 as the case may be; provided further that if, at the time of such withdrawal, the Holders have learned of
a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information, then the
Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Section 2.1(a) or Section 2.1(b). All Selling Expenses relating to Registrable Securities registered
pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 

2.7 Delay of Registration . No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any
registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification . If any Registrable Securities are included in a registration statement under this Section 2: 

(a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers,
directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the
meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in
connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(a) shall not apply to
amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they
arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in
connection with such registration. 
 (b) To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify
and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the
Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent
that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each
such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as

  
 10 

 such expenses are incurred; provided, however, that the indemnity agreement contained in this
Section 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further
that in no event shall any indemnity under this Section 2.8(b) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such
Holder. 
 (c) Promptly after receipt by an indemnified party under this Section 2.8 of notice of the commencement of any
action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.8,
give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to
which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without
conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be
inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the
commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.8, to the extent that such failure materially prejudices the indemnifying party’s ability to defend
such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 2.8. 

(d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either (i) any party
otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the
expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Section 2.8 provides for indemnification in such case, or
(ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Section 2.8, then, and in each such case, such parties will contribute to the aggregate
losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in
connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the
indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case, (x) no

  
 11 

 Holder will be required to contribute any amount in excess of the public offering price of all
such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to
contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Section 2.8(d), when combined with the amounts paid or
payable by such Holder pursuant to Section 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the
obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the termination of this
Agreement. 
 2.9 Reports Under Exchange Act . With a view to making available to the Holders the benefits of SEC Rule 144 and any
other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall: 

(a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times
after the effective date of the registration statement filed by the Company for the IPO; 
 (b) use commercially reasonable efforts to file
with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a
written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities
Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any
time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in
availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form
S-3 (at any time after the Company so qualifies to use such form). 

  
 12 

 2.10 Limitations on Subsequent Registration Rights . From and after the date of this
Agreement, the Company shall not, without the prior written consent of the Holders of at least sixty-six and two thirds percent (66 2/3%) of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder
of any securities of the Company that would allow such holder or prospective holder (i) to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in
any such registration only to the extent that the inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included or (ii) to demand registration of any securities held by such holder or
prospective holder. 
 2.11 “Market Stand-off” Agreement . Each Holder hereby
agrees that, if required by the managing underwriter, it will not, during the period commencing on the date of the final prospectus relating to the IPO and ending on the date specified by the Company and the managing underwriter (such period not to
exceed one hundred eighty (180) days in the case of the IPO, which period may be extended upon the request of the managing underwriter for such longer period of time as is necessary to enable such underwriter to issue a research report or to
make a public appearance that relates to an earnings release or announcement by the Company within fifteen (15) days prior to or after the day that is one hundred eighty (180) days after the effective date of the registration statement
relating to such offering, but in any event not to exceed two hundred ten (210) days following the effective date of the registration statement relating to such offering), (i) lend; offer; pledge; sell; contract to sell; sell any option or
contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable
or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement for such offering or (ii) enter into any swap or other arrangement that transfers to another, in whole or in
part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The
foregoing provisions of this Section 2.11 shall apply only to the IPO, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall be applicable to the Holders only if all officers,
directors, and stockholders individually owning more than one percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Series A Preferred Stock and Series B Preferred
Stock) are subject to the same restrictions. The underwriters in connection with such registration are intended third-party beneficiaries of this Section 2.11 and shall have the right, power, and
authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with
this Section 2.11 or that are necessary to give further effect thereto. The Company agrees to use its reasonable efforts to obtain the agreement of the managing underwriter to periodic early releases of portions of the securities subject
to such lock-up agreements upon the request of a Holder to such early release, provided that in the event of any 

  
 13 

 
early release, all Holders will be released on a pro rata basis from such agreements. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company
or the underwriters shall apply pro rata to all Holders subject to such agreements, based on the number of shares subject to such agreements. 

2.12 Restrictions on Transfer. 

(a) The Series A Preferred Stock, the Series B Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise
transferred, and the Company shall not recognize any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferring
Holder will cause any proposed purchaser, pledgee, or transferee of the Series A Preferred Stock, the Series B Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. 
 (b) Each certificate or instrument representing (i) the Series A
Preferred Stock, (ii) the Series B Preferred Stock, (iii) the Registrable Securities, and (iv) any other securities issued in respect of the securities referenced in clauses (i), (ii) and (iii), upon any stock split, stock
dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of Section 2.12(c)) be stamped or otherwise imprinted with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in its records and giving instructions
to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12. 

(c) The holder of each certificate representing Restricted Securities, by acceptance thereof, agrees to comply in all respects with the
provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof
shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably
requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, 

  
 14 

 
and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the
Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that
action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration
under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will
not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144 or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no
consideration; provided that each transferee agrees in writing to be subject to the terms of this Section 2.12. Each certificate or instrument evidencing the Restricted Securities transferred as above provided shall bear, except
if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Section 2.12(b), except that such certificate shall not bear such restrictive legend if, in the opinion of counsel for such Holder
and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act. 
 2.13
Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Section 2.1 or Section 2.2 shall terminate upon the earliest to
occur of: 
 (a) the closing of a Sale of the Company (as defined in the Stockholders Agreement); 

(b) following the IPO, such time as SEC Rule 144 or another similar exemption under the Securities Act is available for the sale of all of
such Holder’s shares without limitation during a three-month period without registration; and 
 (c) the third (3rd) anniversary of the IPO. 
 3. Information and Observer Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor the required items listed below. 

(a) as soon as practicable, but in any event within one hundred fifty (150) days after the end of each fiscal year of the Company,
(i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and (iii) a statement of stockholders’ equity as of the end of such year, all such financial statements audited and
certified by independent public accountants of nationally or regionally recognized standing selected by the Company and approved by the Board of Directors; 

(b) as soon as practicable but in any event within forty-five (45) days after the end of each of the first three (3) quarters of
each fiscal year of the Company, unaudited statements of income and of cash flows for such fiscal quarter, and an unaudited balance sheet 

  
 15 

 
and a statement of stockholders’ equity as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal
year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 
 (c) if requested
in writing by a Major Investor with respect to a month within five (5) business days of the end of such month, as soon as practicable, but in any event within thirty (30) days after the date of such request, an unaudited income statement
and statement of cash flows for such month, and an unaudited balance sheet and statement of stockholders’ equity as of the end of such month, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to
normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 
 (d) as soon
as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and
securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the
exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit each Major Investor to calculate their
respective percentage equity ownership in the Company, and certified by the chief financial officer or chief executive officer of the Company as being true, complete, and correct. 

(e) as soon as practicable, but in any event fifteen (15) days before the end of each fiscal year, a budget and business plan for the
next fiscal year (collectively, the “Budget”), approved by the Board of Directors and prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after
prepared, any other budgets or revised budgets prepared by the Company; and 
 (f) such other information relating to the financial
condition, business, or corporate affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Section 3.1 to provide information
(i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or (ii) the disclosure of which would
adversely affect the attorney-client privilege between the Company and its counsel. 
 If, for any period, the Company has any subsidiary whose accounts are
consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated
subsidiaries. 
 Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease providing the information set forth in
this Section 3.1 during the period starting with the date thirty (30) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the
SEC rules applicable to 

  
 16 

 such registration statement and related offering; provided that the Company’s covenants under this
Section 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective. 

3.2 Inspection. The Company shall permit each Major Investor, at such Major Investor’s expense, to visit and inspect the
Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor;
provided, however, that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any information that it reasonably considers to be a trade secret or confidential information (unless covered by an
enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

3.3 Termination of Information Rights. The covenants set forth in Sections 3.1 and 3.2 shall terminate and be of no further force or
effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon the closing of a Sale of
the Company, as such term is defined in the Stockholders Agreement. 
 3.4 Confidentiality. Each Investor agrees that such Investor
will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of
the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.4 by such Investor),
(b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any
obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent
necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the
provisions of this Section 3.4; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs
such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such
disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 
 4. Rights to Future Stock Issuances
.. 
 4.1 Right of First Offer . Subject to the terms and conditions of this Section 4.1 and applicable securities laws, if
the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby granted to it among itself and its
Affiliates in such proportions as it deems appropriate. 

  
 17 

 (a) The Company shall give notice (the “Offer Notice”) to each Major Investor,
stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b) By notification to the Company within twenty (20) days after the Offer Notice is given, each Major Investor may elect to purchase or
otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or
exercise, as applicable, of the Series A Preferred Stock, Series B Preferred Stock and any other Derivative Securities then held, by such Major Investor bears to the total number of shares of Common Stock of the Company then outstanding (assuming
full conversion and/or exercise, as applicable, of all Series A Preferred Stock, Series B Preferred Stock and other Derivative Securities). At the expiration of such twenty (20) day period, the Company shall promptly notify each Major Investor
that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has
given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors were
entitled to subscribe but that were not subscribed for by the Major Investors, which is equal to the proportion that the Common Stock issued and held, or issuable upon conversion of Series A Preferred Stock, Series B Preferred Stock and any other
Derivative Securities then held, by such Fully Exercising Investor bears to the total number of shares of Common Stock issued and held, or issuable (directly or indirectly) upon conversion of the Series A Preferred Stock, Series B Preferred Stock
and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Section 4.1(b) shall occur within the later of one hundred twenty
(120) days after the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Section 4.1(c). 

(c) If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in
Section 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Section 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any
Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such
agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Major Investors in accordance
with this Section 4.1. 
 (d) The right of first offer in this Section 4.1 shall not be applicable to
(i) Exempted Securities (as defined in the Company’s Certificate of Incorporation) and (ii) shares of Common Stock issued in the IPO. 

  
 18 

 4.2 Termination. The covenants set forth in Section 4.1 shall terminate and be
of no further force or effect (i) immediately before but subject to the consummation of an IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or
(iii) upon a Sale of the Company, as such term is defined in the Stockholders Agreement. 
 5. Additional Covenants. 

5.1 Insurance. Within a reasonable period of time after requested by the Board of Directors, the Company shall obtain from financially
sound and reputable insurers Directors and Officers Errors and Omissions insurance in an amount satisfactory to the Board of Directors, and will use commercially reasonable efforts to cause such insurance policies to be maintained until such time as
the Board of Directors determines that such insurance should be discontinued. 
 5.2 Employee Agreements. The Company will cause
(i) each person now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure
and proprietary rights assignment agreement and (ii) each Key Employee to enter into a one (1) year noncompetition and nonsolicitation agreement (to the extent permitted by applicable law), substantially in the form approved by the Board
of Directors, including the Series A Directors. In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted stock agreement between the Company
and any employee, without the approval by the Board of Directors, including the Series A Directors. 
 5.3 Employee Vesting. Unless
otherwise approved by the Board of Directors, which approval shall include the Series A Directors , all current and future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the
Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for (i) vesting of shares not faster than over a four (4) year period, with the first
twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting in equal monthly installments over the following three (3) years, and (ii) a
market stand-off provision substantially similar to that in Section 2.11. In addition, unless otherwise approved by the Board of Directors, including the Series A Directors, the Company shall retain a “right of first refusal”
on employee transfers until the Company’s IPO and shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock. 

5.4 Reserved. 

  
 19 

 5.5 Matters Requiring Investor Director Approval. So long as any shares of Series A
Preferred Stock remain outstanding, the Company hereby covenants and agrees with each of the Investors that it shall not, without first obtaining the approval of the Board of Directors, which approval must include the affirmative vote of at least
two (2) Series A Directors (or at least one (1) Series A Director, at any time when there are fewer than two (2) Series A Directors then serving): 

(a) make, or permit any subsidiary to make, any loan or advance to, or own any stock or other securities of, any subsidiary or other
corporation, partnership, or other entity unless it is wholly owned by the Company; 
 (b) make, or permit any subsidiary to make, any loan
or advance to any Person, including, without limitation, any employee or director of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan
approved by the Board of Directors; 
 (c) guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or
indirectly, any indebtedness except for trade accounts of the Company or any subsidiary arising in the ordinary course of business; 
 (d)
make any investment inconsistent with any investment policy approved by the Board of Directors; 
 (e) incur any indebtedness in excess of
$100,000 in the aggregate that is not covered by the Budget, other than trade credit incurred in the ordinary course of business; 
 (f)
otherwise enter into or be a party to any transaction with any director, officer or employee of the Company or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person; 

(g) hire, terminate, or change the compensation of the executive officers, including approving or amending the terms of any option grants or
stock awards to executive officers; 
 (h) change the principal business of the Company, or enter into a new line of business, or exit the
existing line of business of the Company; 
 (i) sell, assign, license, pledge or encumber material technology or intellectual property; or

 (j) enter into any corporate strategic relationship involving the payment contribution or assignment by the Company or to the Company of
money or assets greater than $250,000. 
 5.6 Meetings of the Board of Directors; Committees. Unless otherwise determined at least by
the vote of a majority of the directors then in office, the Board of Directors shall meet at least four (4) times per year, and at least once per quarter, in accordance with an agreed-upon schedule, unless otherwise agreed by a vote of the
majority of the directors. Each non-employee director shall be entitled in such person’s discretion to be a member of any committee of the Board of Directors. 

  
 20 

 5.7 Successor Indemnification. If the Company or any of its successors or assignees
consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the
Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s By-laws, its
Certificate of Incorporation, or elsewhere, as the case may be. 
 5.8 Board Expenses. The Company shall reimburse all non-employee
directors for all reasonable out-of-pocket expenses incurred (consistent with the Company’s policies) in connection with their role as a director of the Company. 

5.9 Directors’ Liability and Indemnification. 

(a) The Company’s Certificate of Incorporation and Bylaws (as such Certificate of Incorporation and Bylaws of the Company may be amended
from time to time) shall provide (i) for limitation of the liability of directors to the maximum extent permitted by law, and (ii) for indemnification of directors for acts on behalf of the Company to the maximum extent permitted by law.
In the event any suit is filed or claim is asserted against a director or former director of the Company as a result of such director’s or former director’s service on the Board of Directors, the Company will provide such director or
former director access to all records and files of the Company as he or she may reasonably request in defending against or preparing to defend against any such suit or claim. 

The Company hereby acknowledges that one or more of the directors nominated by holders of Series A Preferred Stock may have certain rights to
indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and certain of their affiliates (collectively, the “Fund Indemnitors”) for alleged acts or omissions in their capacities as directors
of the Company. The Company hereby agrees (i) that it is the indemnitor of first resort (i.e., its obligations to any such director are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the
same expenses or liabilities incurred by such director are secondary), (ii) that it shall be required to advance the full amount of expenses incurred by such director and shall be liable for the full amount of all expenses, judgments,
penalties, fines and amounts paid in settlement by or on behalf of any such director to the extent legally permitted and as required by the Company’s Certificate of Incorporation or the Bylaws of the Company (or any agreement between the
Company and such director), without regard to any rights such director may have against the Fund Indemnitors, and, (iii) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund
Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of any such director with respect to any claim for which such
director has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such
director against the Company. 

  
 21 

 5.10 Termination of Covenants. The covenants set forth in this Section 5, except for
Sections 5.7 and 5.9, shall terminate and be of no further force or effect (i) immediately before but subject to the consummation of an IPO, (ii) when the Company first becomes subject to the periodic reporting requirements
of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Sale of the Company, as such term is defined in the Stockholders Agreement, whichever event occurs first. 

6. Miscellaneous. 
 6.1
Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate, partner, member, limited partner, retired
partner, retired member, or stockholder of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such
transfer, holds at least 1,000,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided, however, that (x) the Company is, within a
reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written
instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Section 2.11. For the purposes of determining the number of shares of Registrable Securities held
by a transferee, the holdings of a transferee (1) that is an Affiliate, limited partner, retired partner, member, retired member, or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust
for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify individually for
assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon
the respective successors and permitted assignees of the parties, including without limitation, the Investor’s affiliated partnership or funds management by such Investor or any of its respective directors, officers or partners. Nothing in this
Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as
expressly provided herein. 
 6.2 Governing Law. This Agreement shall be governed by and construed in accordance with the General
Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the State of California, without regard to conflict of law
principles that would result in the application of any law other than the law of the State of California. 
 6.3 Counterparts;
Facsimile. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may also be executed and delivered by
facsimile signature and in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

  
 22 

 6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for
convenience only and are not to be considered in construing or interpreting this Agreement. 
 6.5 Notices. All notices, requests,
and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given, delivered and received (i) upon personal delivery to the party to be notified; (ii) when sent by confirmed
electronic mail or facsimile if sent during normal business hours of the recipient, and if not so confirmed, then on the next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt
requested, postage prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, specifying next-day delivery, with written verification of receipt. All communications shall be sent
to the respective parties only at their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address,
facsimile number, or address as subsequently modified by written notice by the applicable party given in accordance with this Section 6.5. If notice is given to the Company, a copy which shall not constitute notice shall also be sent to
Mitchell S. Bloom, Esq. at Goodwin Procter LLP, 53 State St., Exchange Place, Boston, MA 02109. 
 6.6 Amendments and Waivers. Any
term of this Agreement, including without limitation Section 4.1, may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively)
only with the written consent of the Company and the holders of at least sixty-six and two thirds percent (66 2/3%) of the Registrable Securities held by the Investors; provided that the Company may in its sole discretion waive compliance
with Section 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Section 2.12(c) shall be deemed to be a waiver); and provided further
that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party. Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term
hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of
Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the
Company, purchase securities in such transaction); provided, that, if Investors holding at least a majority of the then-outstanding Series B Preferred Stock do not provide such waiver with respect to a particular transaction, the holders of
the Series B Preferred Stock that do not provide such waiver shall have the right to participate in such transaction on substantially similar terms to the Investors providing such waiver. Notwithstanding the foregoing, Section 2.11 and
this sentence of Section 6.6 may not be amended in a manner that adversely affects the Investors without the consent of Investors holding at least sixty-six and two thirds percent (66 2/3%) of the then-outstanding Series B Preferred
Stock. The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, 

  
 23 

 termination, or waiver. Any amendment, termination, or waiver effected in accordance with this
Section 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be
deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 
 6.7 Severability. In case
any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and
such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 

6.8 Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the
purpose of determining the availability of any rights under this Agreement and such Affiliated person may apportion such rights as among themselves in any manner they deem appropriate. 

6.9 Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and
agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. Upon the effectiveness of this Agreement, the
Prior Agreement shall be deemed amended and restated and superseded and replaced in its entirety by this Agreement, and shall be of no further force or effect. 

6.10 Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon
any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or
to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law
or otherwise afforded to any party, shall be cumulative and not alternative. 
 6.11 Submission to Jurisdiction. The parties hereto
submit to the exclusive jurisdiction of any federal or state court located within the State of California over any dispute arising out of or relating to the Agreement or any of the transactions contemplated hereby and each party hereby agree that
all claims in respect of such dispute or any suit, action or proceeding related thereto may be heard and determined in such courts. The parties waive, to the fullest extent permitted by applicable law, any objection which they may not or hereafter
have to the laying of venue of any such dispute brought in such court or any defense of inconvenient forum for the maintenance of such dispute. Each of the parties hereto agrees that a judgment in any such dispute may be enforced in other
jurisdictions by suit on the judgment or in any other manner provided by law. 
 [Remainder of Page Intentionally Left Blank] 

  
 24 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first written above. 
  

			
	COMPANY:
	
	 GLOBAL BLOOD THERAPEUTICS, INC.

		
	By:	 	 /s/ Ted W. Love. M.D.

	Name:	 	Ted W. Love, M.D.
	Title:	 	President and Chief Executive Officer
	
	Address:
	 400 East Jamie Court, Suite 101

South San Francisco, CA 94080

	Attention: President

 [Signature Page to Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	THIRD ROCK VENTURES II, L.P.
		
	By:		Third Rock Ventures GP II, L.P., its general partner
	By:		TRV GP II, LLC, its general partner
		
	By:		 /s/ Kevin Gillis

	Name:		Kevin Gillis
	Title:		CFO
	
	THIRD ROCK VENTURES III, L.P.
		
	By:		Third Rock Ventures GP III, L.P., its general partner
	By:		TRV GP III, LLC, its general partner
		
	By:		 /s/ Kevin Gillis

	Name:		Kevin Gillis
	Title:		CFO

 [Signature Page to Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	FIDELITY SELECT PORTFOLIOS: BIOTECHNOLOGY PORTFOLIO
		
	By:		 /s/ Stacie M. Smith

	Name:		Stacie M. Smith
	Title:		Authorized Signatory
	
	FIDELITY ADVISOR SERIES VII: FIDELITY ADVISOR BIOTECHNOLOGY FUND
		
	By:		 /s/ Stacie M. Smith

	Name:		Stacie M. Smith
	Title:		Authorized Signatory

 [Signature Page to Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	HADLEY HARBOR MASTER INVESTORS (CAYMAN) L.P.
		
	By:		Wellington Management Company, LLP
			its investment advisor
		
	By:		 /s/ Steven M. Hoffman

	Name:		Steven M. Hoffman
	Title:		Vice President and Counsel
	
	SALTHILL INVESTORS (BERMUDA) L.P.
		
	By:		Wellington Management Company, LLP
			its investment advisor
		
	By:		 /s/ Steven M. Hoffman

	Name:		Steven M. Hoffman
	Title:		Vice President and Counsel
	
	SALTHILL PARTNERS L.P.
		
	By:		Wellington Management Company, LLP
			its investment advisor
		
	By:		 /s/ Steven M. Hoffman

	Name:		Steven M. Hoffman
	Title:		Vice President and Counsel

 [Signature Page to Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	RA CAPITAL HEALTHCARE FUND, LP
		
	By:		 /s/ Peter Kolchinsky

	Name:		Peter Kolchinsky
	Title:		Manager

 [Signature Page to Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	PERCEPTIVE LIFE SCIENCES MASTER FUND LTD
		
	By:		 /s/ James H. Mannix

	Name:		James H. Mannix
	Title:		COO
	
	TITAN PERC, LTD
		
	By:		 /s/ Darren Ross

	Name:		Darren Ross
	Title:		Director

 [Signature Page to Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	SABBY HEALTHCARE MASTER FUND, LTD.
		
	By:		Sabby Management, LLC, its Investment Manager
		
	By:		 /s/ Robert Grundstein

	Name:		Robert Grundstein
	Title:		COO and General Counsel

 [Signature Page to Amended and Restated Investors’ Rights Agreement] 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights
Agreement as of the date first written above. 
  

							
	INVESTOR:
	
	DEERFIELD SPECIAL SITUATIONS FUND, L.P.
		
	By:		Deerfield Mgmt, L.P.
			General Partner
			
			By:		J.E. Flynn Capital, LLC
					General Partner
				
					By:		 /s/ David J. Clark

					Name:		David J. Clark
					Title:		Authorized Signatory
	
	DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P.
		
	By:		Deerfield Mgmt, L.P.
			General Partner
			
			By:		J.E. Flynn Capital, LLC
					General Partner
				
					By:		 /s/ David J. Clark

					Name:		David J. Clark
					Title:		Authorized Signatory
	
	DEERFIELD PRIVATE DESIGN FUND III, L.P.
		
	By:		Deerfield Mgmt III, L.P.
			General Partner
			
			By:		J.E. Flynn Capital III, LLC
					General Partner
				
					By:		 /s/ David J. Clark

					Name:		David J. Clark
					Title:		Authorized Signatory

 [Signature Page to Amended and Restated Investors’ Rights Agreement] 

			
	 IN WITNESS WHEREOF, the parties have

executed this Amended and Restated Investors’
 Rights
Agreement as of the date first written above.

	
	INVESTOR:
	
	COWEN GBT INVESTMENT LLC
		
	By:		Cowen Investments LLC, its Managing Member
		
	By:		 /s/ Owen Littman

	Name:		Owen Littman
	Title:		Authorized Signatory

 [Signature Page to Amended and Restated Investors’ Rights Agreement] 

 SCHEDULE A 

 

	
	
	Name and Contact of Investors
	
	 THIRD ROCK VENTURES II, L.P.

29 Newbury Street; 3rd Floor

Boston, MA 02116
 Phone:
(617)585-2000
 Fax: (617) 859-2891

Attn: Kevin Gillis and Kevin Starr

	
	 THIRD ROCK VENTURES III, L.P.

29 Newbury Street; 3rd Floor

Boston, MA 02116
 Phone:
(617)585-2000
 Fax: (617) 859-2891

Attn: Kevin Gillis and Kevin Starr

	
	 FIDELITY SELECT PORTFOLIOS: BIOTECHNOLOGY PORTFOLIO

Brown Brothers Harriman & Co

525 Washington Blvd.
 Jersey City,
NJ 07310
 Email: Michael.lerman@bbh.com

Fax: (617) 772-2418
 Attn:
Michael Lerman 15th Floor Corporate Actions

	
	 FIDELITY ADVISORS SERIES VII: FIDELITY ADVISOR BIOTECHNOLOGY FUND

State Street Bank & Trust

P.O. Box 5756
 Boston, MA 02206

Email: SSBCORPACTIONS@StateStreet.com

Fax: (617) 988-9110
 Attn:
Bangle & Co fbo Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund

	
	
	 HADLEY HARBOR MASTER INVESTORS (CAYMAN) L.P.

c/o Wellington Management Company, LLP

280 Congress Street
 Boston,
Massachusetts 02210
 Email: seclaw@wellington.com

Fax: (617) 289-5699
 Attn: Legal
and Compliance Department

	
	 SALTHILL INVESTORS (BERMUDA) L.P.

c/o Wellington Management Company, LLP

280 Congress Street
 Boston,
Massachusetts 02210
 Email: seclaw@wellington.com

Fax: (617) 289-5699
 Attn:
Legal and Compliance Department

	
	 SALTHILL PARTNERS, L.P.

c/o Wellington Management Company, LLP

280 Congress Street
 Boston,
Massachusetts 02210
 Email: seclaw@wellington.com

Fax: (617) 289-5699
 Attn:
Legal and Compliance Department

	
	 RA CAPITAL HEALTHCARE FUND, LP

20 Park Plaza, Suite 1200
 Boston,
MA 02116
 Email: pkolchinsky@racap.com

Fax: (617) 778-2510
 Attn:
Peter Kolchinsky

	
	 PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

499 Park Avenue, 25th Floor

New York, NY 10022
 Phone:
(646) 205-5340
 Fax: (646) 205-5301

Attn: James H. Mannix

	
	
	 TITAN PERC, LTD

750 Washington Blvd., 10th Floor

Stamford, CT 06901
 Phone: (203)
327-8650
 Email: dross@titanadvisors.com

Fax: (203) 327-8599
 Attn: Darren
Ross

	
	 SABBY HEALTHCARE MASTER FUND, LTD.

10 Mountainview Road, Suite 205

Upper Saddle River, NJ 07458
 Phone:
(646) 307-4527
 Fax: (201) 661-8654

Attn: Robert Grundstein

	
	 DEERFIELD SPECIAL SITUATIONS FUND, L.P.

780 Third Avenue
 New York, NY
10017
 Phone: (212) 692-7124

Fax: (212) 692-7125
 Attn:
David J. Clark

	
	 DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P.

780 Third Avenue
 New York, NY
10017
 Phone: (212) 692-7124

Fax: (212) 692-7125
 Attn:
David J. Clark

	
	 DEERFIELD PRIVATE DESIGN FUND III, L.P.

780 Third Avenue
 New York, NY
10017
 Phone: (212) 692-7124

Fax: (212) 692-7125
 Attn:
David J. Clark

	
	
	 COWEN GBT INVESTMENT LLC

C/O Cowen Investments LLC
 599
Lexington Avenue
 New York, NY 10022

Phone: (212) 201-4841
 Fax: (212)
201-4840
 Attn: Owen Littman

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}]]